Navigating the Parkinson's Path - 2021

August 7, 2021 @ 8:00AM — 12:00PM Central Time (US & Canada)

The Peterson Foundation for Parkinson's (PFP)'s annual EXPO Navigating the Parkinson’s Path: Insights and Information for Improved Living is designed to education, engage and empower the Parkinson’s community. In addition to an in-person event, the organization will also provide a virtual platform for individuals unable to attend the event in person.

Navigating the Parkinson's Path - 2021 image

Education, Movement, Exhibitors

There are currently no tickets available for this event, but you can still make a donation.

Share:

FEATURED PRESENTATIONS:

Dr. Thomas Davis: Living and Progression of Parkinson’s Disease / Research Updates

Dr. Davis specializes in the treatment of movement disorders and has been a member of the American Board of Psychiatry and Neurology since 1990. In addition to maintaining his clinical research activities and teaching responsibilities, he is currently director of the Division of Movement Disorders, Medical Director of the Vanderbilt Parkinson’s Foundation Center of Excellence, an attending physician at Vanderbilt University Medical Center, and a staff neurologist at the Nashville Veterans Administration Hospital.

Dr. Peter Hedera: Moving Forward: Learning more about Parkinson’s disease and how it advances.

Dr. Hedera is a board certified neurologist and medical geneticist who specializes in the management and treatment of movement disorders. His clinical interests include surgical therapies for Parkinson’s disease, essential tremor and dystonia, and botulinum toxin procedures for dystonia and spasticity. He has 21 years of experience in the field of movement disorders and neurogenetic conditions.

Dr. William Petrie: Mental Health Awareness and Parkinson’s

Dr. Petrie is Professor of Clinical Psychiatry and Behavioral Sciences, and directs the outpatient geriatric psychiatry clinic. His clinical interests and activity includes psychiatric aspects of Parkinson’s disease, the use of clozapine in elderly patients, and impulse disorders in neurodegenerative illnesses, and psychopharmacologic interventions in the elderly.